Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 2
- 主要终点
- Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to <70% (Particularly in the Anterior Rectum)
研究概览
简要总结
The purpose is to determine if use of rectal spacers are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects. It is also to determine whether it provides sufficient dosimetric benefits to warrant further clinical investigation in future SABR (Stereotactic Ablative Body Radiation) related clinical studies.
详细描述
A phase II study to assess safety and efficacy of the spacer injection process, ability of the spacer to effectively provide the space necessary to reduce acute events in the rectum, and also meet the SABR based rectal constraints, and to monitor stability of this process during SABR. Unlike IMRT, which uses smaller dose/fraction, when using such high dose/fraction, even a few mm of shift in spacer positioning may impact the dose that the rectum receives, and therefore, a rigorous study of stability of material during the SABR treatments will need to be determined. If there is some shift, by doing this study, we may be able to determine the margin of error that will be necessary in considering rectal organ dosimetry, based on the possible shift in positiong that may occur with the spacer over time.
As the SABR therapy is strictly local, we will select for patients with prostate cancer locally confined to the prostate gland. As such, we will select eligibility criteria of low risk patients to minimize risk of extraprostatic spread, seminal vesicle invasion, and nodal spread. Hormonal therapy may also be used to shrink prostates that are massively enlarged as this may also help further reduce length of rectum that will be irradiated. As the primary toxicity will likely be mucosal damage, we will avoid enrolling patients with pre-existing mucosal dysfunction (including those with previous radiation, TURP, very large prostate glands, inflammatory bowel disease) and immunosuppressed individuals based on our phase I experience[13]. In this way, patients will be uniformly selected in a fashion that would identify patients likely to receive benefit from the therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •All patients must be willing and capable to provide informed consent to participate in the protocol.
- •Eligible patients must have appropriate staging studies identifying them as AJCC stage T1 (a, b, or c) or T2a or T2b adenocarcinoma of the prostate gland. The patient should not have direct evidence of regional or distant metastases after appropriate staging studies. Histologic confirmation of cancer will be required by biopsy performed within 180 days of registration.
- •The patient's Zubrod performance status must be 0-
- •The Gleason score should be less than or equal to 6 or 3+4 if < 50% of a 12 core biopsy was involved.
- •The serum PSA should be less than or equal to 10 ng/ml.
- •Study entry PSA must not be obtained during the following time frames: 10 day period following prostate biopsy; following initiation of ADT; within 30 days after discontinuation of finasteride; or within 90 days after discontinuation of dutasteride.
- •Age ≥ 18 years.
- •Patients may have used prior hormonal therapy, but it should be limited to no more than 9 months of therapy prior to enrollment.
- •The ultrasound, or CT based volume estimation of the patient's prostate gland should be ≤ 60 grams.
排除标准
- •Subjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery for prostate cancer.
- •Subjects who have plans to receive other concomitant or post treatment adjuvant antineoplastic therapy while on this protocol including surgery, cryotherapy, conventionally fractionated radiotherapy, hormonal therapy, or chemotherapy given as part of the treatment of prostate cancer.
- •Subjects who have undergone previous transurethral resection of the prostate (TURP) or cryotherapy to the prostate. Subjects who have significant urinary obstructive symptoms; AUA score must be ≤15 (alpha blockers allowed).
- •Subjects who have a history of significant psychiatric illness.
- •Men of reproductive potential who do not agree that they or their partner will use an effective contraceptive method such as condom/diaphragm and spermacidal foam, intrauterine device (IUD), or prescription birth control pills.
- •Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
- •Severe, active co-morbidity, defined as follows:
- •Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
- •Transmural myocardial infarction within the last 6 months.
- •Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- •Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration.
- •Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.
- •Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
- •Patients with history of inflammatory colitis (including Crohn's Disease and Ulcerative colitis) are not eligible.
- •Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR).
- •Subjects with evidence of extraprostatic extension (T3a) or seminal vesicle involvement (T3b) on clinical evaluation.
研究组 & 干预措施
No Arm
Study did not have Arm(s)
干预措施: Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent) (Device)
结局指标
主要结局
Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to <70% (Particularly in the Anterior Rectum)
时间窗: Median 9 months within the end of radiation treatment
The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects
Effectiveness of Space Creation of >= 7.5 mm in Protecting Rectum From Toxicity
时间窗: Median 9 months within the end of radiation treatment
The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects
次要结局
- Percentage of Participants With Spacer Related Acute Toxicity(270 days)
- Determine Spacer's Ability to Change Percent Rectal Circumference (PRC) Receiving 39 Gy(1 month)
- Determine Spacer's Ability to Change Percent Rectal Circumference (PRC) Receiving 24 Gy.(1 month)
- Acute (Within 270 Days of Treatment) SABR-related Gastrointestinal (GI) Toxicities(270 days)
- Acute (Within 270 Days of Treatment) SABR-related Genitourinary (GU) Toxicities(270 days)
- Chronic (>270 Days From Treatment) SABR-related Genitourinary (GU) Toxicities(From day 271 up to 540 days)
- Chronic (>270 Days From Treatment) SABR-related Gastrointestinal (GI) Toxicities(From day 271 up to 540 days)
- Acute Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity- Irritative(270 days)
- Acute Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity-Obstructive(270 days)
- Acute Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity-Reproductive.(270 days)
- Chronic Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity-Obstructive.(From day 271 up to 540 days)
- Chronic Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity-Reproductive.(From day 271 up to 540 days)
- Chronic Non-GI (Gastrointestinal) and Non-GU (Genitourinary) Toxicity-Irritative.(From day 271 up to 540 days)
- Freedom From Biochemical Recurrence(4 year)
- Overall Survival(5 year)
- Disease-specific Survival(5 year)
- Local Relapse(3 year)
- Regional Relapse(3 years)
- Distant Relapse(3 years)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Function(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Frequency(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bloody Stools(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Habits(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Urgency(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Leakage/Fecal Incontinence(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Bowel Pelvic/Rectal Pain(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Urinary Function(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Urinary Irritative/Obstructive(18 months)
- EPIC (Expanded Prostate Cancer Index Composite) Urinary Incontinence(18 months)
- AUA (American Urological Association) Quality of Life Questionnaire(18 months)
研究者
Michael Folkert
Associate Professor of Medicine
University of Texas Southwestern Medical Center